Urology Research

Efficacy of Yishen Tongluo Formula Combined with Sulodexide in the Treatment of Diabetic Nephropathy with Renal Failure

Lin Li, Chenchen Li, Limin Zhang, Juan Ji, Yan Gao, Wei Qin — Wed, 08 Jan 2025 00:00:00 +0800

Objective: To analyze the effect of Yishen Tongluo Formula combined with sulodexide in treating patients with diabetic nephropathy and renal failure. Methods: A hundred patients with diabetic nephropathy accompanied by renal failure who were admitted to the hospital for treatment from March 2021 to March 2024 were randomly divided into the control group and the observation group, and were treated with sulodexide therapy and Yishen Tongluo Formula + sulodexide therapy, respectively. The treatment efficacy of the two groups was evaluated. Results: After treatment, fasting blood glucose and other levels were lower in the observation group, P < 0.05; renal function indexes in the observation group improved, where levels of 24-hour urinary protein, blood urea nitrogen, and blood creatinine were significantly lower than those of the pre-treatment and control group; the effect of microinflammatory state relief was significant, as demonstrated by the significant decrease of interleukin-6 and other indexes, P < 0.05. Conclusion: In the treatment of diabetic nephropathy patients with renal failure, we should pay attention to the protection of renal function, applying sulodexide to improve patients’ blood glucose indexes, and at the same time, utilizing Yishen Tongluo Formula to alleviate patients’ microinflammatory state and enhance the recovery of renal function.

Analysis of the Efficacy of Finerenone Combined with Irbesartan in the Treatment of Diabetic Nephropathy

Chenchen Li, Lin Li, Limin Zhang, Juan Ji, Zhe Li, Jing Li — Wed, 08 Jan 2025 00:00:00 +0800

Objective: To analyze the clinical effect of using finerenone combined with irbesartan in the treatment of diabetic nephropathy. Methods: Eighty-five patients with diabetic nephropathy who received inpatient treatment in our hospital from July 2023 to June 2024 were selected and divided into the control group (42 cases) and the observation group (43 cases) according to the differences in drug treatment programs. The control group received oral treatment with finerenone tablets, and the observation group received treatment with finerenone combined with irbesartan. The differences in the blood glucose level, renal function indicators, serological level, and adverse reactions of the two groups were compared and analyzed. Results: After treatment, the levels of fasting blood glucose, 2-hour postprandial blood glucose, glycated hemoglobin, blood creatinine, urea nitrogen, blood uric acid, TGF-β1, SFRP-4, GSK-3β, and ICAM-1 in the observation group were significantly lower than those in the control group (P < 0.05). In the control group, there was one case each of vertigo, palpitation, rash, vomiting, and angioneurotic edema during treatment, with a total incidence rate of 11.90%; the observation group had one case each of vertigo and vomiting, with a total incidence rate of 4.65% (P > 0.05). Conclusion: In the clinical treatment of patients with diabetic nephropathy, finerenone combined with irbesartan therapy can significantly improve patients’ blood glucose level and serological levels, and alleviate patients’ renal function, showing positive clinical application value.

Clinical Efficacy of Tamsulosin Combined with Huang’e Capsules in Improving Type III Prostatitis

Qiang Ren, Hankai Chen, Jinfeng Yu, Junbiao Zheng, Yumin Li, Dong Li — Wed, 08 Jan 2025 00:00:00 +0800

Objective: To explore the clinical efficacy and safety of tamsulosin combined with Huang’e capsules in treating type Ⅲ prostatitis. Methods: A total of 74 patients from the Department of Urology at Jiaxing University Affiliated Jiashan Hospital were selected and randomly divided into treatment group and control group by double-blind method, with 37 cases in each group. The treatment group was given tamsulosin combined with Huang’e capsules, and the control group was given tamsulosin alone. The NIH-CPSI, IIEF-5, and EPS-WBC scores and the incidence of adverse reactions in the two groups were compared before treatment as well as 15 and 30 days after treatment. Results: The treatment group showed statistically significant differences compared to the control group in terms of pain or discomfort, urinary symptoms, quality of life, NIH-CPSI, and EPS-WBC after treatment (P < 0.05). There was no statistically significant difference in IIEF-5 scores between the two groups (P > 0.05). No major adverse reactions occurred in either group during the treatment. Conclusion: Tamsulosin combined with Huang’e capsules can effectively improve the clinical symptoms of patients with type III prostatitis, enhance the quality of life, and has good safety.